Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Set to Announce Quarterly Earnings on Monday

Key Points

• Shionogi is expected to report quarterly earnings after Monday’s market close, with analysts forecasting $0.13 in EPS and $1.11 billion in revenue.
• The company’s prior quarter exceeded expectations, reporting $0.36 EPS versus the $0.18 consensus estimate and $1.04 billion in revenue against a $970.69 million forecast.
• Analyst sentiment is strongly positive: three analysts rate the stock a Strong Buy, while Jefferies and Zacks Research recently upgraded their recommendations.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) is expected to be releasing its results after the market closes on Monday, October 26th. Analysts expect Shionogi & Co., Ltd. Unsponsored ADR to post earnings of $0.13 per share and revenue of $1.11 billion for the quarter.

Shionogi & Co., Ltd. Unsponsored ADR (OTCMKTS:SGIOY - Get Free Report) last announced its earnings results on Monday, August 3rd. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.18. The company had revenue of $1.04 billion for the quarter, compared to the consensus estimate of $970.69 million. Shionogi & Co., Ltd. Unsponsored ADR had a net margin of 46.67% and a return on equity of 16.13%. On average, analysts expect Shionogi & Co., Ltd. Unsponsored ADR to post $0.82 EPS for the current fiscal year and $0.79 EPS for the next fiscal year.

Shionogi & Co., Ltd. Unsponsored ADR Price Performance

SGIOY opened at $9.22 on Monday. The stock has a fifty day moving average of $9.07 and a 200-day moving average of $9.26. The firm has a market capitalization of $15.69 billion, a P/E ratio of 9.22, a PEG ratio of 3.29 and a beta of 0.08. Shionogi & Co., Ltd. Unsponsored ADR has a 12-month low of $7.83 and a 12-month high of $12.00. The company has a quick ratio of 1.00, a current ratio of 1.14 and a debt-to-equity ratio of 0.01.

Analysts Set New Price Targets

Several research firms recently weighed in on SGIOY. Jefferies Financial Group raised Shionogi & Co., Ltd. Unsponsored ADR from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, July 14th. Zacks Research raised Shionogi & Co., Ltd. Unsponsored ADR from a "hold" rating to a "strong-buy" rating in a research note on Thursday. Three analysts have rated the stock with a Strong Buy rating. Based on data from MarketBeat, the company has a consensus rating of "Strong Buy".

About Shionogi & Co., Ltd. Unsponsored ADR

Shionogi & Co, Ltd. is a Japanese pharmaceutical company headquartered in Osaka, Japan. Founded in 1878, the company researches, develops, manufactures and markets prescription medicines, with a longstanding focus on infectious diseases and specialty therapies.

Its products and development programs have included Xofluza (baloxavir marboxil), an oral treatment for influenza; Fetroja (cefiderocol), an antibiotic for certain difficult-to-treat Gram-negative bacterial infections; and medicines for central nervous system disorders, pain and other therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.